Randomized trial · people

Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large 72-week trial, daily oral orforglipron led to more weight loss than placebo at every dose tested, with gut side effects as the most common problem.

Kind
Randomized trial
Studied in
People
Number studied
3127
Published
2025
Journal
N Engl J Med

What they tested

The team tested whether once-daily orforglipron, taken by mouth, lowers body weight more than placebo in adults with obesity who do not have diabetes.

How the study was done

A phase 3, multinational, randomized, double-blind, placebo-controlled trial in 3127 adults with obesity and no diabetes, who took orforglipron at 6 mg, 12 mg or 36 mg, or placebo (a dummy treatment), once a day for 72 weeks. Everyone also followed a healthy diet and physical activity.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 72 weeks, average body weight changed by -7.5% in the 6 mg arm, -8.4% in the 12 mg arm and -11.2% in the 36 mg arm, compared with -2.1% on placebo, and each dose beat placebo. In the 36 mg arm, 54.6% lost at least 10% of their weight, 36.0% lost at least 15% and 18.4% lost at least 20%, compared with 12.9%, 5.9% and 2.8% on placebo. Waist size, systolic blood pressure (the top number), triglycerides and non-HDL cholesterol also improved more than on placebo. Side effects led 5.3 to 10.3% of people on orforglipron to stop treatment, versus 2.7% on placebo, and the most common were gut-related effects that were mostly mild to moderate.

What it doesn’t show

The trial included only adults with obesity who did not have diabetes, and it compared orforglipron with placebo, not with other weight-loss medicines. It was funded by Eli Lilly.

The paper

Wharton et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025.

The compound

More studies on Orforglipron

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo